Company / Cash & Equivalents
Enliven Therapeutics, Inc. Cash & Equivalents History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$124.1M
FY2024
5-year range
$47.7M / $124.1M
FY2020-FY2024
Trend
+23.9%
vs FY2023
Sector context
#128 of 207
Health Care
What the data says
At $124M, Enliven Therapeutics, Inc.'s cash & equivalents ranks #128 of 207 in the Health Care sector. Cash & Equivalents has increased for 5 consecutive years, from $5M in FY2019 to $124M in FY2024.
Based on SEC 10-K filings.
$124M in FY2024 with a 5-year CAGR of +90.6%.
Improved from $76M to $124M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +37.0%
- 5-Year CAGR
- +90.6%
- 10-Year CAGR
- -
Sector benchmark
#128 of 207 in Health CareTop 62% of 207This company $124.1M Sector average $669.5M
▼
-81.5% below sector average
Key checks
Key Insights
- Enliven Therapeutics, Inc.'s cash & equivalents has grown for 5 consecutive years.
- 5-year CAGR of +90.6%, indicating consistent growth.
- In FY2024, cash & equivalents increased 23.9% year-over-year.
- Ranks #128 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $124.1M | +23.9% |
| FY2023 | $100.1M | +32.6% |
| FY2022 | $75.5M | +56.4% |
| FY2021 | $48.3M | +1.3% |
| FY2020 | $47.7M | +866.3% |
| FY2019 | $4.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026